About Echo Therapeutics

Echo Therapeutics is focused on transdermal medical devices and specialtypharmaceuticals. Echo's Symphony(TM) tCGM System is in late-stage developmentas a non-invasive (needle-free), wireless, transdermal continuous glucosemonitoring (tCGM) system for patients with Type 1 and Type 2 diabetes and foruse in hospital critical care units. Echo's AzoneTS reformulation technologyis focused on building a pipeline of safer and improved versions of widely-prescribed, FDA-approved specialty pharmaceutical products. Echo's SymphonytCGM System consists of its wireless transmission and transdermal biosensortechnologies and its Prelude(TM) SkinPrep System, which incorporates leading-edge, needle-free skin permeation control. Echo expects the Symphony tCGMSystem to provide both diabetics and hospital professionals with a reliable,affordable, comfortable-to-wear, and easy-to-use, needle-free continuousglucose monitoring device.

Forward-Looking Statements

This press release contains forward-looking information that involvesrisks and uncertainties, including statements regarding Echo's developmentplans, objectives, expectations and intentions, including, without limitation,statements regarding the Company's Symphony tCGM System and AzoneTS productcandidates. Factors that could adversely affect Echo's business and prospectsare described in the Company's filings with the Securities and ExchangeCommission. Echo expressly disclaims any obligation or undertaking to releasepublicly any updates or revisions to any such statements to reflect any changein the Company's expectations or any change in events, conditions orcircumstances on which any such statement is based.

Investor Relations Contacts: Patrick T. Mooney, M.D. Chairman & CEO Echo Therapeutics 508-530-0329 Lilian Stern Stern Investor Relations 212-362-1200SOURCE Echo Therapeutics, Inc.